Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?

The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Thumallapally, Nishitha, Yu, Hana, Asti, Divya, Vennepureddy, Adarsh, Terjanian, Terenig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981158/
https://www.ncbi.nlm.nih.gov/pubmed/27540299
http://dx.doi.org/10.2147/OTT.S110189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981158/
https://www.ncbi.nlm.nih.gov/pubmed/27540299
http://dx.doi.org/10.2147/OTT.S110189

Ejemplares similares